Research
Hormonal
SGLT2 inhibitors (flozins) such as dapagliflozin and empagliflozin show promise in reducing liver steatosis and inflammation in MAFLD patients, with several Phase 3 and 4 trials ongoing.
SGLT2 inhibitors like dapagliflozin and empagliflozin are oral diabetes drugs that are being studied for MAFLD. They help reduce liver fat and inflammation, and may also help with weight loss. They are not yet approved specifically for MASH, but trials are ongoing.
GoodQualifiesHIGH confidence
Reduction of inflammation, steatosis and fibrosis have been suggested as beneficial effects on the liver, for which the clinical efficacy of SGLT2 inhibitors is being investigated in numerous RCTs [1,74,75].
Why this rating
Based on ongoing Phase 3/4 trials and some published results.
Source
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development
Farah Khaznadar et al. · Current Issues in Molecular Biology · 2024
DOI 10.3390/cimb46070376
narrative_reviewCited 13×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Resmetirom (Rezdiffra), a thyroid hormone receptor-beta (THR-β) agonist, is the first FDA-approved pharmacotherapy for non-cirrhotic MASH in adults with moderate to advanced liver fibrosis (F2-F3), demonstrating significant resolution of MASH and improvement in liver fibrosis compared to placebo.Strong
- Pegozafermin (BIO89-100), an FGF-21 analog, demonstrates improvement in liver fibrosis in patients with MASH, as shown in Phase 2b trials, and has entered Phase 3 clinical trials.Good
- Semaglutide, a GLP-1 receptor agonist, significantly reduces hepatic steatosis, inflammation, and liver stiffness in patients with MAFLD, although its effect on reducing fibrosis stage remains uncertain.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →